Many possible answers here, but I have been using zanubrutinib + obino in this setting as in the ROSEWOOD study. Zinzani et al., PMID 37506346 While not compared directly to rituximab + rev, it certainly looks better. Don’t want to repeat benda and impair T cell function for future CAR-T ...